Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Arch Biopartners Inc V.ARCH

Alternate Symbol(s):  ACHFF

Arch Biopartners Inc. is a late-stage clinical trial company focused on preventing acute kidney injury. The Company is developing a platform of new drugs to prevent inflammation injury in the kidneys, lungs and liver via the dipeptidase-1 (DPEP1) pathway and are relevant for many common injuries and diseases where organ inflammation is an unmet problem. The Company’s lead drug candidate is LSALT Peptide. The Company is engaged in the clinical development of LSALT Peptide and other DPEP-1 targeting drug candidates for indications where inflammation of the lungs, liver and kidneys is an unmet problem. LSALT Peptide is in a second phase II trial, targeting the prevention and treatment of cardiac surgery-associated acute kidney injury (CS-AKI). The Company has additional technology platforms in its portfolio, which are AB569 and Borg. AB569 is an anti-infective candidate for treating or preventing antibiotic resistant bacterial infections, primarily as a topical treatment for wounds.


TSXV:ARCH - Post by User

Post by Viking2233on Apr 02, 2024 7:43am
181 Views
Post# 35964496

3 more sites

3 more sitesGood newd continues to flow in here. 3 more sites in Turkey now dosing. My best guess the original 3 sites have already dosed about 15 people.

I would suggest that the new sites would not have been added if initial dosing results were negative so I see this as a very bullish sign

We have one site in Calgary coming on line soon, it would be nice to see one of the major heart hospitals in Toronto or Montreal to join the trial.

It has been over two weeks since Arch released data from published British 3rd party peer review from lung data phase 2 trial. Remember Raymond James analyst was waiting 2 years for this yet not a word from this analyst, plus the company has started a new phase 2 AKI study with 6 locations in Turkey and 1 in Canada. We are also now dosing at a much higher strength. We are going to start another phase 2 trial in the fall with a re-purposed drug that is already proven safe. Again no comment from RJ Analyst.

I wonder if this analyst is even covering Arch anymore????


<< Previous
Bullboard Posts
Next >>